Tonix prelim 2025: net loss $118.9M vs $130.0M; cash $207.6M funds ops into Q1 2027

Tonix Pharmaceuticals Holding Corp.

2025-FY EPS reported -$14.57 vs consensus -$3.25 ▼ miss (-347.8%)

Cash & equivalents $207.6M at Dec 31, 2025; 12.79M shares outstanding as of Jan 30, 2026.
Net loss $118.9M (2025) vs $130.0M (2024); net cash used in operations $99.0M vs $60.9M.
Net product revenue $13.1M (2025) vs $10.1M (2024); Zembrace/Tosymra $11.7M vs $10.1M.
TONMYA launch Nov 17, 2025 generated $1.4M from launch to Dec 31, 2025.
Capital expenditures $3.4M in 2025 vs $0.1M in 2024; cash expected to fund ops into Q1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.